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Elucidating the genetic control of cerebral cortical
(pallial) development is essential for understanding
function, evolution, and disorders of the brain. Tran-
scription factors (TFs) that embryonically regulate
pallial regionalization are expressed in gradients,
raising the question of how discrete domains are
generated. We provide evidence that small enhancer
elements active in protodomains integrate broad
transcriptional information. CreERT2 and GFP
expression from 14 different enhancer elements in
stable transgenic mice allowed us to define a
comprehensive regional fate map of the pallium.
We explored transcriptional mechanisms that control
the activity of the enhancers using informatics, in vivo
occupancy by TFs that regulate cortical patterning
(CoupTFI, Pax6, and Pbx1), and analysis of enhancer
activity in Pax6 mutants. Overall, the results provide
insights into how broadly expressed patterning TFs
regulate the activity of small enhancer elements
that drive gene expression in pallial protodomains
that fate map to distinct cortical regions.
INTRODUCTION
At the core of cortical development lie transcriptional programs
that orchestrate a sequence of processes beginning with spec-
ification of the cortical anlage and its regional subdivisions, or
the protomap (Rakic, 2009; O’Leary et al., 2013). Ongoingwork has identified a set of transcription factors (TFs) that control
the size and areal identities of pallial subdivisions. These include
CoupTFI, Dmrta2 (Dmrt5), Emx2, Lef1, Lhx2, Pax6, and Sp8
(Bishop et al., 2000; Galceran et al., 2000; Yun et al., 2001;
Mallamaci and Stoykova, 2006; Armentano et al., 2007;
Sahara et al., 2007; Faedo et al., 2008; Mangale et al., 2008;
Chou et al., 2009; Konno et al., 2012; Borello et al., 2013; Saulnier
et al., 2013). Each of these TFs is expressed in distinct gradients
in progenitor cells of the pallial ventricular zone (VZ). For
instance, Pax6 is expressed in rostrocaudal and ventrodorsal
gradients; Pax6 loss of function in mice results in a respecifica-
tion of cortical regions along both its rostrocaudal and ventro-
dorsal axes (Bishop et al., 2000; Yun et al., 2001). Despite the
subdivision of the pallium into discrete structural/molecular units
(e.g., the medial, dorsal, lateral, and ventral pallium [MP, DP, LP,
and VP]; Puelles et al., 2000), to date the TFs that are known to
control regional fate are expressed in gradients across these
subdivisions, raising the intriguing question of how these gradi-
ents are interpreted in an integrative fashion to generate sharply
delineated pallial subdivisions and later adult cortical regions.
One mechanism that could solve this conundrum would be
that enhancer elements integrate TF expression to generate
gene activation in distinct pallial subdivisions, much in the way
that regional fate is generated in the cellular blastoderm of
Drosophila embryos (Lagha et al., 2012). While this general para-
digm had previously been supported through anecdotal reports
of individual pallial enhancers identified in gene-centric studies
(Kammandel et al., 1999; Theil et al., 2002; van den Bout et al.,
2002; Ahituv et al., 2007; Colasante et al., 2008), a recent more
comprehensive screen for forebrain enhancers that includes
spatial activity data for 145 human enhancers that are active
in the embryonic day (E) 11.5 mouse telencephalon enables a
rigorous and systematic search for enhancers involved inNeuron 82, 989–1003, June 4, 2014 ª2014 Elsevier Inc. 989
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Enhancers Active in Cortical Protodomainsprepatterning of the pallium (Visel et al., 2013). Here we present
evidence that enhancers integrate information from TF gradients
in the embryonic day E11.5 mouse pallium to generate distinct
expression domains. Using a panel of 14 human enhancers care-
fully selected based on their in vivo activity patterns, we gener-
ated a set of stable mouse transgenic lines that express CreERT2
and GFP in distinct domains within the developing pallium.
Leveraging this unique set of reporter mice, we derived fate
maps that elucidate the embryonic origin of pallial subdivisions.
Furthermore, we used a combination of bioinformatics, chro-
matin immunoprecipitation sequencing (ChIP-seq), and in vivo
studies to elucidate the regulation of these enhancers by major
pallial transcription factors including COUPTFI, PAX6, and
PBX1. Overall, we propose that the enhancers defined through
this study identify protodomains of the pallial neuroepithelium,
which may be fundamental units of cortical development and
evolution.
RESULTS
Pallial Protodomains Identified by Enhancer Activity
Using Transient Transgenic Assay
To define enhancers potentially marking neuroepithelial subdivi-
sions in the E11.5 pallium, wemined a previously described large
collection of enhancers active in the developing telencephalon,
assayed using transient transgenic mouse LacZ expression
(Visel et al., 2013). We identified more than 40 enhancers that
showed regional pallial expression, many of which showed intra-
pallial boundaries (Figures 1A–1C and Figure S1 available
online). For instance, in the MP, several enhancer lines showed
nested patterns of expression, varying between a small dorso-
caudal domain (643), a domain in the ventral caudomedial
telencephalon (653), a larger domain that includes the entire cau-
domedial telencephalon (192), and the entire dorsomedial and
caudomedial region including the primordial septum (348) (Fig-
ure 1C). Regional patterns of activity were also observed for
enhancers expressed in the DP, LP, and VP (Figures 1A and
1B). We mapped these expression limits onto a model schema
of the E11.5 pallial neuroepithelium, from which we hypothesize
the existence of a set of sharply delimited pallial progenitor
domains or protodomains (A-I) (Figure 1D; Table S1).
Enhancer Activity of Pallial Enhancer CreERT2-IRES-
GFP Alleles
To test the idea that these human enhancers are active in proto-
domains that generate distinct pallial subdivisions, we produced
stable transgenic mouse lines to characterize the properties of
14 enhancers that reproducibly exhibited boundaries in the
E11.5 pallium (Figures 1A–1C and Figure S1; asterisks label
the enhancers used to make stable lines).
We generated stable transgenic mouse lines that express
CreERT2-IRES-GFP and downstream of each one of the 14
selected ‘‘pallial’’ enhancers and a minimal Hsp68 promoter.
We generated two to three founders for 10/14 of the lines; their
expression domains were reproducible (Table S2). We further
analyzed the properties of one founder for each enhancer.
To characterize the activity of each enhancer, we defined the
GFP expression at E11.5 and compared the enhancer activity990 Neuron 82, 989–1003, June 4, 2014 ª2014 Elsevier Inc.in the stable and transient transgenic assays. The stable lines
showed enhancer activity patterns that closely resembled the
transient transgenic assay (Table S2). We annotated the E11.5
expression domains on a flattened topologic representation of
the embryonic pallium (right hemisphere), where stippled gray
color indicates GFP expression (Figures 2I and 2I0 and Figures
S2A–S2N). For instance, for enhancer 643, we observed progen-
itor GFP expression in the MP at E11.5 (Figures 2A–2H). On the
other hand, enhancer 1,050 showed progenitor GFP expression
in the DP and MP at E11.5 but was absent in the ventrolateral
pallium (VLP) (Figures 2A0–2H0).
Next, we examined prenatal GFP expression at E12.5, E14.5,
and E17.5 for all of the lines (Figures S2A–S2N and Table S2).
In most cases, enhancer activity was strongest at E11.5 and
was largely unchangedat E12.5 (TableS2).However, activity pat-
terns of someof the enhancersweremoredynamic. For instance,
636 was selectively active in the VLP at E10.5, but by E11.5, its
activity was greatly reduced (Figure S2E). Activity of 12/14 en-
hancers decreased and/or became restricted to a smaller
domain by E14.5 and E17.5 (Table S2). For instance, 218, 281,
653, and 1,318 activity was no longer detected in the pallium by
E14.5. Three of the enhancers with MP expression (348, 643,
and 1,006) were no longer active in the hippocampus but main-
tained activity in the hippocampal fissure, choroid plexus, and
fimbrial area. The activity of 636, 840, and 1,172 became
restricted to small populations of cells in the palliumat E17.5 (Fig-
ures S2E, S2I, and S2M). Enhancer 660, which was active in the
caudoventral MP at E11.5, became active in the SVZ and super-
ficial cortical layers of the DP at E17.5 (Figure S2H).
FateMappingUsingPallial EnhancerCreERT2-IRES-GFP
Alleles
To determine the identity of the cells whose progenitors have
E11.5 enhancer activity, we performed fate map analyses by
introducing the Ai14 (tdTomato) Cre reporter allele (Madisen
et al., 2010) into the enhancer CreERT2-IRES-GFP lines. We
administered tamoxifen at E10.5 to induce CreERT2 transloca-
tion to the nucleus, where it activated tdTomato expression
and then performed neuroanatomical analyses at later stages.
Because of the 24–36 hr window of tamoxifen action (Hayashi
and McMahon, 2002), we assessed enhancer activity at both
E11.5 and E12.5 to better interpret the results of E10.5 tamoxifen
treatment (Figure S2 and Table S2). Since prenatal tamoxifen
treatment frequently led to fetal death around the time of deliv-
ery, we obtained fate-mapping data at E17.5 for all enhancer
lines. However, we also obtained postnatal fate maps (P30) for
a subset of the enhancers (192, 348, 636, 643, 653, and 660; Fig-
ure S2 and Table S3). We chose these enhancers because of
their activity in the hippocampus; the hippocampusmatures later
than the neocortex; thus, P30 data helped analysis of the hippo-
campal fate map.
We annotated the fate map domains on a flattened topological
representation of the maturing/mature pallium (Figures 2S and
2S0 and Figure S2). Here we indicated anatomical locations con-
taining tdTomato+ cells using a graded rating scale of 1–4: 1 (red)
high density to 4 (green) almost no tdTomato+ cells (Figures 2S
and 2S0). For instance, 643, which showed E11.5 activity
restricted to the MP, fate mapped to the rostrodorsal CA fields,
Figure 1. Enhancer Activity Assays at E11.5 of Transient Transgenics Expressing b-Galactosidase from the LacZ Gene
Asterisk indicates that stable transgenic lines were made using these enhancers. Coronal sections across the rostrocaudal telencephalon were studied for 15
different enhancers.
(A) Five enhancers with a nested pattern of LacZ expression in the dorsal pallium.
(B) Five enhancers with a nested pattern of LacZ expression in the lateroventral pallium.
(C) Five enhancers with a nested pattern of LacZ expression in the medial pallium.
(D) Schema of coronal sections across the rostrocaudal telencephalon showing progenitor domains and boundaries deduced from analysis of enhancer-driven
expression patterns.
(E) Schema of coronal sections across the rostrocaudal telencephalon showing progenitor domains and boundaries (A-M) deduced from analysis of enhancer
activity fate mapping (see subsequent figures). Some boundaries are specific to rostral (r), whereas other boundaries are specific to caudal (c) regions. See also
Figure S1. For abbreviations, see legend to Figure 2.
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Enhancers Active in Cortical Protodomainsdentate gyrus of the rostrodorsal hippocampus, the fimbrial
area, and choroid plexus (Figures 2J–2R and 5B–5B0 0 0). On the
other hand, 1,050, which showed E11.5 activity restricted toDP and MP, was fate mapped to the neocortex and hippocam-
pus and only weakly labeled the LP (insular cortex) and did not
label the VP (piriform cortex) (Figures 2J0–2R0).Neuron 82, 989–1003, June 4, 2014 ª2014 Elsevier Inc. 991
Figure 2. Analyses of Enhancers 643 and
1,050
(A–H0 and J–R0) Enhancer activity (GFP expression,
E11.5; A–H0) and fate-mapping (Cre-induced
tdTomato, E17.5; J–R0) assays of stable transgenics
encoding enhancer 643 (left) or 1,050 (right). (C0) and
(E0 0) show higher-magnification view of E11.5
expression.
(I and I0) Schemas showing approximate position of
GFP expression (gray) within flattened view of E11.5
pallial progenitor zones of enhancers 643 (I) and
1,050 (I0).
(S and S0 ) Schemas showing approximate position
of dtTomato expression within flattened view of
E17.5 pallial subdivisions; color coded according
to approximate density of tdTomato+ cells of
enhancers 643 (S) and 1,050 (S0).
Abbreviations according to region: ventral pallium
(VPall, allopallium): AO, anterior olfactory nuclei;
OB, olfactory bulb; Pir/EPir, piriform and ectopiri-
form; LERh, lateral entorhinal; MERh, medial ento-
rhinal; lateral pallium (LPall, mesopallium): Ins/Cl,
insula/claustrum; LO, lateral orbital; PRh, perirhinal;
Orb, orbitofrontal; dorsal pallium (DPall; neo-
pallium): AU (A), auditory; DPF, dorsal prefrontal; F,
frontal; LPF, lateral prefrontal; M, motor; SS,
somatosensory; V, visual; dorsomedial pallium
(DMPall): Cing (C), cingulate gyrus; IL, infralimbic
(and PrL, prelimbic); MOrb, medial orbital; RSP,
retrosplenial; PoRh, postrhinal; medial pallium
(MPall): CA1–3, CA fields 1–3; DG, dentate gyrus; fi
(F), fimbria; IG, indusium griseum; Sub (S), sub-
iculum; PaS, parasubiculm; PrS, presubiculum; TT,
tenia tecta; dorsal midline: bac, brachium of the
anterior commissure; bcc, brachium of the corpus
callosum; bhc, brachium of the hippocampal
commissure; ch, choroid plexus; PSe (PS), pallial
septum; pallial amygdala (Pall Amygd): AA, anterior
amygdala; Ahi, amygdalohippocampal area; BM,
basomedial; BLA, basolateral; LA, lateral; sub-
pallium: Acb, accumbens; CGE, caudal ganglionic
eminence; Dg, Diagonal area; LGE, lateral gangli-
onic eminence; MGE, medial ganglionic eminence;
Pal, pallidum; SPSe, subpallial septum; St, striatum;
hypothalamus: hp1, 2, hypothalamic prosomere 1
and 2; PHy, peduncular; Thy, hypothalamus; dien-
cephalon: Hb, habenula; p2, p3, prosomeres 2 and
3; Thy, terminal hypothalamus; PThE, prethalamic
eminence; Th, thalamus.
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Enhancers Active in Cortical ProtodomainsSimilar analyses were performed for all the enhancer lines;
the data and analyses are compiled in Figures S2A–S2N.
From these experiments, we have deciphered the embryonic
origin of pallial subdivisions (see schema of pallial progenitor
subdivisions in Figure 1E and Tables S3 and S4); we have
organized these data into Figures 3, 4, and 5, which focus992 Neuron 82, 989–1003, June 4, 2014 ª2014 Elsevier Inc.on the frontal cortex, ventrolateral cortex,
and hippocampal structures, respectively.
Enhancers Active in Primordia of
Distinct Frontal Cortex Subdivisions
The analysis of E11.5 expression and
CreERT2 fate-mapping experiments from11 enhancer transgenic lines demonstrated which progenitor
domains generated cells that populated different subdivisions
of the prefrontal cortex (PFC) (Figure 3 and Figure S2; Tables
S3 and S4). Fate mapping of enhancer lines (192, 348,
1,056) with E11.5 activity in the rostral-most E11.5 MP resulted
in labeled cells in the medial PFC (MPFC). Enhancer 192
Figure 3. Frontal Cortex Analysis
(A–H0 0 0) Eight enhancers with activity in pallial progenitors that fate map to prefrontal cortex subdivisions: medial: 192, 1,056, 348; dorsal: 1,050, 840; and lateral:
636, 281, 1,172. Coronal sections through prefrontal cortex are shown: left column shows GFP expression at E11.5 in situ or immunohistochemistry. Right
columns show fate mapping with tdTomato expression in an E17.5 rostrocaudal series. See Figure S2 for additional E11.5 and E17.5 sections.
(I) Annotation of fate-mapping results from selected enhancers (y axis) in five regions of the frontal cortex (x axis). Different levels of density of tdTomato
expression are estimated and described as high density (red), medium density (orange), low density (yellow), and negligible density (green). In some cases, we
note subdomain expression.
(J) Deduced progenitor domain organization of the rostral E11.5 pallium. For abbreviations, see legend to Figure 2 and the following: CR, Cajal Retzius cells;
DPFC, dorsal prefrontal; DLGE, dorsal LGE; FP, frontal pole; MPFC, medial prefrontal; SP, subpallium.
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Enhancers Active in Cortical Protodomainsactivity generated tissue probably representing the indusium
griseum and taenia tecta (Figures 3A–3A0 0 0 and Figure S2A);
1,056 generated the ventromedial PFC (including the medialorbital cortex) (Figures 3B–3B0 0 0 and Figure S2L); 348 gener-
ated most regions of the MPFC (Figures 3C–3C0 0 0 and
Figure S2D).Neuron 82, 989–1003, June 4, 2014 ª2014 Elsevier Inc. 993
(legend on next page)
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Enhancers Active in Cortical ProtodomainsFate mapping of enhancer lines (218, 840, and 1,050) with
E11.5 activity in the rostral-most DP (Figure 3, Figure S2, and
Table S4) resulted in labeling of the dorsal PFC (DPFC). For
instance, 1,050 only generated cells in the DPFC (Figures 3D–
3D0 0 0 and Figure S2K).
Fate mapping of enhancer lines (281, 636, and 1,172) that
showed expression in the rostral-most E11.5 VLP (Figure 3 and
Figure S2) resulted in cells of the lateral PFC (LPFC). This
included the anterior insular cortex and the lateral orbital PFC
(Figure 3 and Figure S2). Finally, fate mapping of 1,318 and
1,006 activities, which were similar in the rostral telencephalic
pole at E11.5, resulted in cells that populate the entire PFC (Fig-
ure 3I and Figures S2J and S2N). These data are summarized in
Figure 3I, Figure S2, and Tables S3 and S4.
Enhancers Active in Primordia of Distinct VP and LP
Subdivisions
The analysis of E11.5 expression and CreERT2 fate-mapping ex-
periments from eight enhancer transgenic lines identified pro-
genitor domains generating the VP and LP, which contain
cortical domains superficial to pallial nuclei (Puelles, 2014) (Fig-
ures 4K and Figure S2). To systematize the E17.5 fate-mapping
analyses, we compared the td-Tomato expression with the
expression of two proteins that have boundaries in the VP and
LP domains: NURR1 (NR4A2) and CTIP2 (BCL11B) (Figure 4).
NURR1 was expressed dorsally in the claustrum, a nucleus lying
deep to the insular cortex (LP) and more ventrally in the dorsal
endopiriform nucleus, which is deep to the piriform cortex (VP).
We defined boundary 1 as the dorsal limit of the claustrum and
boundary 3 as the ventral limit of the endopiriform nuclei (Figures
4B–4B0 0 0, 4E–4E0 0 0, and 4H–4H0 0 0). CTIP2 was expressed in the
superficial corticoid strata of these two pallial regions; we
defined boundary 2 as the limit between the insular cortex and
the piriform cortex and boundary 4 as the ventral limit of the
VP with the subpallium (Figures 4C–4C0 0 0, 4F–4F0 0 0, and 4I–4I0 0 0).
Fate maps from the ventrolateral enhancers (Figures 4 and S2)
showed different tdTomato+ cell distributions in the ventrolateral
cortices. Rostrally, enhancers 1,050, 1,006, 218, 281, and 636
showed progressively more ventral boundaries. Cells marked
by 1,050 activity were restricted to the DP (ending before the
LP), 1,006 ended roughly at the DP/LP boundary, 218 ended
roughly at the LP/VP boundary, and 281 and 636 extended to
the pallial-subpallial boundary (Figures 4A–4F0 0 0 and Figures
S2C, S2E, and S2J). Enhancer 636 was most active in the VLP,
with little activity in the DP (Figures 4A–4C0 0 0 and Figure S2E).
Figure 4J shows enhancer fate map annotation along the
dorsoventral axis in separate rostral, middle, and caudal regions.
Some enhancers had clear rostrocaudal differences in theFigure 4. Four Enhancers with Activity in Pallial Progenitors that Fate
(A–I0 0) Left column shows GFP protein (green fluorescence) or RNA (purple in situ
Right columns show fate mapping with tdTomato expression at E17.5. To map t
tdTomato (red) and either Nurr1 or Ctip2 (green). Nurr1 or Ctip2 expression was
limits of the fate maps of 636, 281, and 218.
(J) Annotation of fate-mapping results from selected enhancers (y axis) in nine reg
expression are estimated and described as high density (red), medium density (o
(K) Deduced progenitor domain organization of middle-to-caudal regions of th
abbreviations, see legend to Figure 2 and the following: Cl, claustrum; EPir, enddorsoventral position of their respective fate maps (281, 636,
1,172, and 1,318). For instance, 1,172 labeled a domain that
rostrally was largely ventrally restricted, whereas caudally it
extended into the DP and MP (Figure S2M). Note that enhancer
1,172 maps to a genomic region 100 kb away from CoupTFI,
which shows a very similar expression pattern (Figure S2M,
Table S2; Armentano et al., 2007; Faedo et al., 2008).
Enhancers Active in Primordia of MP Subdivisions:
Hippocampal Complex and Adjacent Structures
E11.5 expression and fate-mapping experiments from six
enhancer transgenic lines demonstrate the progenitor domains
that generate different MP derivatives; these enhancers were
active either in the rostrodorsal or caudoventral hippocampal
fields (Figures 5, 6F, and 6G and Figure S2). Note that the dorso-
ventral adult hippocampal topography corresponds topologically
to the embryonic rostrocaudal axis, the ventral tip next to the
amygdala being caudalmost. The hippocampal region is topolog-
icallydorsal; the choroidplexus (Ch) is thedorsalmostcomponent.
CreERT2 fate mapping from enhancers 192, 218, 348, and 643
generated a nested pattern of derivatives within the hippocam-
pal complex. Enhancer 192 activity was the most restricted; its
derivatives contributed to the choroid plexus, fimbrial area
(F or hem), and hem-originated Cajal Retzius (CR) cells, with
very sparse labeling of the dentate gyrus and CA fields (Figures
5C–5C0 0 0 and Figure S2A). Enhancer 643 was active in the pro-
genitors of the Ch, F, CR cells, dentate gyrus (DG), and CA fields
(strongest in CA1) (Figures 5B–5B0 0 0 and Figure S2F). Its activity
was restricted to the rostrodorsal MP. Likewise, 218 was active
in progenitors of the rostrodorsal MP but was weak in caudoven-
tral MP progenitors (Figure S2B). Enhancer 348 was active in the
entire MP but with stronger activity in its rostrodorsal compo-
nents (Figures 5A–5A0 0 0 and 5D–5D0 0 and Figure S2D).
By contrast with these rostrodorsal MP enhancers, we identi-
fied twoMP enhancers that were almost exclusively restricted to
the caudoventral MP: 653 and 660. These were active in progen-
itors that produced cells in the caudoventral DG and CA fields
(Figures 5E–5E0 0 0 and Figures S2G and S2H).
Enhancer 643 Marks the Formation of the Hippocampal
Field
Based on the nested activity of enhancers 192, 643, and 348
within the hippocampal primordia (GFP expression and fate
maps), we studied its ontogenesis in detail by examining
enhancer MP activity at E11.5 (Figure 6). We compared the
expression of GFP and Lmx1a RNA, a marker of the F and Ch
(Chizhikov et al., 2010). Histochemical analysis at E11.5 showed
that GFP expression from enhancers 192 and 643 and Lmx1aMap to Ventrolateral Cortex Subdivisions
) expression at E10.5 (636; arrowhead: migrating neurons) or E11.5 (281, 218).
he fate map boundaries, we performed double immunofluorescnece to detect
used to define boundaries 1, 2, 3, and 4 (see Results), which distinguished the
ions of the ventrolateral cortex (x axis). Different levels of density of tdTomato
range), low density (yellow), and negligible density (green).
e E11.5 pallium. See Figure S2 for additional E11.5 and E17.5 sections. For
opirifom; OT, olfactory tubercle; Neo, neocortex; P Amgy, pallial amgydala.
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Figure 5. Four Enhancers with Activity in Medial Pallial Progenitors that Fate Map to Hippocampal Subdivisions
Coronal sections show GFP expression at E11.5 and fate mapping with tdTomato expression at P30. Two enhancers show activity and fate map to the ros-
trodorsal hippocampus (348 and 643); P30 fate map pictures are shown at 23 (A0, B0, and C0), 43 (A0 0, B0 0, and C0 0), and 103 (A0 0 0, B0 0 0, and C0 0 0) magnifications.
Enhancer 192 fate maps to the fimbria and choroid plexus. One enhancer (653) shows activity and fate maps to the caudoventral hippocampus and choroid
(legend continued on next page)
Neuron
Enhancers Active in Cortical Protodomains
996 Neuron 82, 989–1003, June 4, 2014 ª2014 Elsevier Inc.
Neuron
Enhancers Active in Cortical ProtodomainsRNA expression were nearly identical; they shared a sharp
boundary (arrowhead; Figures 6A–6A0 0 0 and 6B–6B0 0 0). Likewise
at E12.5, enhancer 192 activity (GFP) and Lmx1a RNA expres-
sion remained nearly identical (arrowhead; Figures 6C–6C0 0),
whereas enhancer 643 GFP expression spread into the adjacent
pallial neuroepithelium (between arrowhead and arrow; Figures
6D–6D0 0). Recall that enhancer 192 fate mapping labeled very
little of the hippocampus, whereas enhancer 643 fate mapping
labeled the DG and the CA fields of the rostrodorsal hippo-
campus (Figures 5C–5C0 0 0, arrows, and 6C). Thus, the hippocam-
pal field is first detectable between E11.5 and E12.5, concomi-
tant with the expansion of enhancer 643 activity (Figure 6E).
Computational Identification of Transcriptional Drivers
of Region-Specific Enhancer Activity
To explore the molecular mechanisms controlling enhancer ac-
tivity in subregions of the pallium, we compared the sequences
of enhancers with activity largely restricted specific pallial do-
mains. We were most successful when we compared MP
enhancer sequences (N = 9; 192, 348, 480, 611, 622, 643, 653,
660, 1,006) to the sequence of enhancers active in DP, LP, and
VP (N = 15; 22, 200, 218, 488, 595, 619, 632, 636, 671, 876,
957, 978, 987, 1,025, 1,050). We searched for nucleotide motifs
that distinguished these groups using two models. Model 1 was
trained to distinguish sequencemotifs between 9MP enhancers,
15 non-MP enhancers, and 480 random genomic sequences.
Model 2 was trained to distinguish sequence motifs between 9
MP enhancers, 15 non-MP enhancers, a set of background se-
quences consisting of 480 random genomic sequences, and
765 sequences from the VISTA Enhancer Browser that were
negative for enhancer activity (see Supplemental Experimental
Procedures). This approach generatedmotifs that were enriched
inMP enhancers compared to non-MP enhancers. The top 20 de
novo motifs for each set of enhancers (MP and non-MP) were
mapped to the Transfac and JASPAR database to identify TFs
that have similar binding sites (Figure S3; see Tables S5 and S6).
Using the list of TF bindingmotifs preferentially identified inMP
enhancers or in non-MP enhancers, we scrutinized the E11.5
expression of the top 40 TFs using the Allen Brain Atlas (http://
developingmouse.brain-map.org/). Five TFs (Lhx5, AR, Nr4a2
[nuclear receptor family], Lmx1a, and Foxj1) were only expressed
in the Ch/F domain, and five TFs showed expression in the DP,
but not in the MP, and especially in Ch/F, expression was either
low or not detectable (Figures S3 and S4 and Tables S5 and S6).
Thus, the method successfully selected for TFs that were either
expressed within or excluded from Ch/F. Of note, the Ch is
perhaps the most distinct region of the pallium, because its
derivative, the choroid plexus, is a nonneural structure.
Transcriptional Mechanisms Regulating Enhancer
Function: In Vivo Binding by PAX6, COUPTFI, and PBX1
Next, we directly screened the enhancers for binding sites for
TFs known to regulate pallial pattering. We found binding sitesplexus; results are compared with the rostrodorsal hippocampal enhance
(D0 0 and E0 0) magnifications. See Figure 6 for fate-mapping annotation and F
legend to Figure 2 and the following: CA1 and CA3, hippocampal pyramidal c
hypothalamus.for PAX6, COUPTFI (NR2F1), and PBX1 in pallial enhancers
(Genomatix); each of these TFs regulates patterning of the
pallial primordium (Bishop et al., 2000; Yun et al., 2001; Malla-
maci and Stoykova, 2006; Armentano et al., 2007; Faedo
et al., 2008; O.G. and J.L.R.R., unpublished data). We then
tested whether these enhancers were bound in vivo by these
TFs using chromatin immunoprecipitation and DNA
sequencing (ChIP-seq). We performed ChIP-seq with anti-
bodies to PAX6 (n = 3), COUPTFI (n = 1), and PBX1 (n = 1)
on dissected E12.5 mouse pallium; information about the qual-
ity of the sequence mapping and peak calling are reported in
Table S7. We surveyed the genome for binding to the 44 en-
hancers assayed in Figure 1 and Figure S1. The results are
organized according to the regional activity of the enhancers,
MP (n = 11), DP+MP (n = 8), DP (n = 2); LVP+DP; LVP
(n = 12), and MP+DP+LVP (n = 6) (Table S8). Then, we anno-
tated ChIP-seq binding to each enhancer by PAX6, COUPTFI,
and PBX1.
PAX6 bound to all of the enhancers that were globally
expressed (MP+DP+LVP) in the pallium (6/6). As the enhancers
became more restricted in their regional activity, PAX6 binding
frequency reduced, particularly if LVP activity was absent.
PAX6 and COUPTFI (NR2F1) bound to few MP enhancers, and
PBX1 bound none (Figure 7A and Table S8). We show an
example of PAX6 peaks over enhancer 840 and 636 (Figure 7C),
and PAX6, COUPTFI, and PBX1 binding over the other
enhancers are shown in Figure S5.
We then focused on Pax6 regulation of some of the enhancers
that had in vivo binding sites. We used transient transfection
luciferase assays to study whether Pax6 cotransfection modu-
lated activity of 636, 643, 840, and 1,172 (n = 4). In each case,
we observed >5-fold activation of luciferase expression (Fig-
ure 7B). Of note, PAX6 activation declined in enhancers with
MP activity (840, 643) or that were expressed in a caudorostral
gradient (1,172; note: Pax6 is expressed in a rostocaudal
gradient).
Finally, we tested Pax6 in vivo regulation of enhancer activity
by introducing the 636, 643, and 840 enhancer-CreERT2-GFP
alleles into mice harboring a Pax6 null allele (Sey). We generated
E11.5 embryos and found that Pax6/ mutants had reduced
GFP expression from enhancers 636 and 840 in pallium (Figures
7D, 7D0, 7F, and 7F0). On the other hand, enhancer 643 continued
to express GFP in the Pax6/ mutant, although the ventral
boundary was less sharp (Figure S5).
DISCUSSION
We generated stable transgenic mouse lines that express
CreERT2 and GFP from 14 different enhancer elements with
activity in distinct domains within the E11.5 pallium. These
enhancer-CreERT2-GFP lines have obvious broad utility for
experimental manipulation of gene expression in specific do-
mains and at specific times, including Cre-mediated gener (348); P30 fate map pictures are shown at 23 (D0 and E0) and 43
igure S2 for additional E11.5 and E17.5 sections. For abbreviations, see
ell fields; DG, dentate gyrus (Do, dorsal; Ve, ventral); HC, hippocampus; Hy,
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Figure 6. Expansion of the Hippocampal Primordium at E12.5
(A–D0) Comparison of the activity of MP enhancers 192 and 643 at E11.5 and E12.5. Enhancer activity (A and B: GFP expression) is compared with Lmx1a RNA
expression (A0 and B0) using double immunohistochemistry (GFP)/in situ hybridization (A0 0 and B0 0: Lmx1a). Lmx1amarks the F/Ch domain; at E11.5, both 192 and
643 have nearly identical patterns, sharing a common boundary (arrowhead). However, by E12.5, enhancer 643 (C and C0) activity expands beyond the Lmx1a/
enhancer 192 (D and D0 ) boundary (arrowhead) into the neuroepithelium that generates the dentate gyrus andCA fields (arrow; see Figures 5C0–C0 0 0); note that 192
activity is present in a few scattered hippocampal progenitors (C, arrows).
(E) Schema summarizing results in (A–D0), showing the expansion of the hippocampus (HC) between E11.5 and E12.5.
(F) Annotation of fate-mapping results from selected enhancers (y axis) in 13 regions of the medial pallium (x axis). Different levels of density of tdTomato
expression are estimated and described as high density (red), medium density (orange), low density (yellow), and negligible density (green).
(G) Deduced progenitor domain organization of E11.5 medial pallium and other regions of the caudal pallium. For abbreviations, see legend to Figure 2.
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Figure 7. Transcription Regulation of Pallial Enhancers
(A) Percentage of enhancers with ChIP-seq peaks for PAX6, COUPTFI, and PBX1 on LVP+DP+MP, LVP; LVP+ DP, DP+MP, and MP enhancers.
(B) Transcription assays in transfected P19 cells (2 days) measuring luciferase expression driven by PAX6 activation of enhancers 636, 840, 643 and 1,172. Error
bars were generated using a one-way ANOVA with a Tukey post hoc test.
(C) PAX6 ChIP-seq analysis from E12.5 cortex showing a peak directly over endogenous enhancer 840 (black bar).
(D) GFP pallial expression driven by enhancer 840 in E11.5 cortex.
(D0) Reduced pallial GFP expression in Pax6/.
(E) PAX6 ChIP-seq analysis from E12.5 cortex showing a peak directly over endogenous enhancer 636 (black bar).
(F) GFP pallial expression driven by enhancer 636 in E11.5 cortex.
(F0) Reduced pallial GFP expression in Pax6/ (asterisk labels migrating VP neurons). See also Figure S5. For abbreviations, see legend to Figure 2 and the
following: CDP and CMP, caudal DP and MP; SPSe, subpallial septum.
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Enhancers Active in Cortical Protodomainsdeletion. Herein, using these unique tools, we (1) determined
comprehensive regional fate map of the mouse pallium, which
includes evidence for a set of progenitor domains defined by
the activity of the enhancers (Figure 1E), and (2) began to
decipher transcriptional mechanisms that control the enhancers
using informatics, in vivo occupancy by TFs that regulate cortical
patterning (PAX6, COUPTFI, and PBX1), and analysis of
enhancer activity in Pax6mutants. Below we elaborate on these
discoveries and their implications for understanding cortical
development, evolution, and disorders.Dynamic Temporal Activity of Cortical Enhancers
Previously published transient transgenic analysis of cortical
enhancers (Visel et al., 2013) interrogated only one develop-
mental time point, E11.5. Using the stable enhancer lines
described in this paper, we analyzed enhancer activity at
different developmental ages. The majority of the enhancers
maintained similar patterns of activity between E11.5 and
E13.5; however, by E14.5, the activity of most of the enhancers
decreased and/or became restricted to a smaller domain (Fig-
ure S2; Table S2). Thus, the set of enhancers we studied wereNeuron 82, 989–1003, June 4, 2014 ª2014 Elsevier Inc. 999
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Enhancers Active in Cortical Protodomainsprimarily active during stages when regional patterning of
pallium takes place (E9.5–E12.5) and at early stages of neuro-
genesis (E11–E13.5), suggesting that other enhancers have
roles at later stages to drive gene expression for later develop-
mental processes. Recently, Nord et al. (2013) provided
evidence for distinct cohorts of enhancers that are active at
different stages of brain development. In addition, some en-
hancers can be active at different stages. For example 660
expression, as its E11.5–E13.5 activity in the caudoventral cortex
wanes, begins at E13.5 in the neocortical subventricular zone
(Figure S2). TheDlxI12b enhancer is active both in subpallial sub-
ventricular zone progenitor cells and in maturing and mature
GABA neurons (Ghanem et al., 2007; Vogt et al., 2014).
Fate-Mapping Analyses Define the Regional Derivatives
from Distinct Pallial Progenitor Domains
The transient transgenic analysis of enhancer E11.5 activity led
us to hypothesize subdivisions of the pallial progenitors (Fig-
ure 1D). The stable transgenic analysis of E11.5 enhancer activity
(GFP expression), and CreERT2 fate analyses at E17.5 and P30,
supported many aspects of our initial model (Figure 1D) and
importantly enabled us to describe the regional fates of each
proposed progenitor domain (Figure 1E and Table S2). Among
the important observations, we discovered E11.5 progenitor
domains that produce distinct subdivisions of the frontral cortex,
providing information about where these distinct regions origi-
nate (Figure 3).
Previous fate mapping of pallial regions have used transplan-
tation (chick-quail; Garcia-Lopez et al., 2009) and Cre recombi-
nation methods, in which a constitutive Cre was driven from a
gene locus. Thus, unlike our study, the previous Cre fate map-
ping did not obtain temporal-specific data, since generally the
alleles were active over long periods of pallial development.
Emx1-Cre and Foxg1 fate mapping showed that expression
from these loci covers most of the pallium (Gorski et al., 2002;
He´bert and McConnell, 2000). Wnt3a-Cre fate mapping labeled
the cortical hem and derived Cajal-Retzius cells (Yoshida et al.,
2006). Dbx1-Cre fate mapping showed that the ventral pallium
is another source for Cajal Retzius cells and that it contributes
glutamatergic neurons to specific nuclei in the amygdala and
ventral cortical structures (Bielle et al., 2005; Hirata et al.,
2009; Teissier et al., 2010;Waclaw et al., 2010). Thus, while these
studies provide important information about the fates of pallial
regions that express Cre over the course development, they do
not provide a comprehensive fate map from multiple pallial
progenitor domains from temporally restricted Cre activity.
The fate maps obtained using the 14 enhancer lines illumi-
nated unexpected facets of the E11.5 expression domains.
There was a rostrocaudal discontinuity in the properties of
dorsomedial progenitor domains (between coronal planes 4
and 5 of schema; Figure 1E); rostrally, next to the septocommis-
sural region, the dorsomedial progenitors generate the motor,
cingulate, and prefrontral cortex; caudally, next to the choroid
plexus, the dorsomedial progenitors generate the hippocampal
complex and fimbrial area (hem). Within the rostral domain, we
observed other rostrocaudal discontinuities, such as the restric-
tion of the pallial septum, IL, and PrL domains within coronal
planes 2 and 3 (Figure 3J).1000 Neuron 82, 989–1003, June 4, 2014 ª2014 Elsevier Inc.Topographic discontinuities in caudal progenitor domains
include the restriction of the Ch and F to the regions illustrated
in coronal planes 4–7, the joining of the caudoventral (caudal)
and rostrodorsal hippocampal domains in coronal plane 8, and
the end of the hippocampal domain in coronal plane 9. Remark-
ably, we identified enhancers only active in the rostrodorsal (218,
348, and 643) or caudoventral (653 and 660) hippocampal
primordia at E11.5.
The relative sizes of some progenitor domainswere dispropor-
tionate to the size of their derived regions at E17.5 and P30, such
as the size of Ch/F compared to the rest of the hippocampal
complex (see sections 5–7; Figures 1E and 6G). Thus, there
was not a 1:1 proportional matching of the sizes of E11.5 progen-
itor and mature domains, providing evidence that the timing and
relative distribution of regional growth is not uniform.
We provided evidence that the hippocampal primordium
begins to expand at E12.5, based on the likewise expanded
activity of enhancer 643 (Figure 6). Furthermore, the activity of
enhancer 1,050 becomes progressively focused in the hippo-
campal region between E11.5 and E14.5 (Figure S2K). Thus,
further investigations into the transcriptional process that drives
hippocampal development will be aided by understanding the
transcription mechanisms that drive enhancer 643 and enhancer
1,050 activities in the hippocampal primordium.
While the aim of our anatomical analyses was to derive a pallial
fate map, we made some observations about regional histogen-
esis and cell-type generation. Tamoxifen induction of recombi-
nation at E10.5 generally resulted in radial clones of cells that
spanned the cortical plate, providing evidence that this set of en-
hancers is not lineage restricted with regard to subsequent
laminar fate. This adds evidence for the model that intrinsically
produced neurons for each cortical layer are sequentially gener-
ated from the same neuroepithelial progenitor (Leone et al.,
2008; Guo et al., 2013), although it does not eliminate the possi-
bility that enhancers will be discovered that showmore restricted
fate properties. Indeed, as has already been elucidated, excit-
atory neurons of layer 1 (Cajal Retzius cells) are generated
from specific domains at the pallial perimeter (Bielle et al.,
2005; Yoshida et al., 2006; Puelles, 2011); several of our
enhancers (192, 348, and 643) provide additional evidence for
this process (Figures S2A, S2D, and S2F). Furthermore, because
the enhancers drive CreERT2, tamoxifen induction of Cre activity
at later time points can be used to study later stages of neuro-
and gliogenesis with enhancer lines that maintain progenitor
cell activity after E11.5 (Table S2).
Identification of Enhancers that Detect Pallial
Subdivisions: Insights into the Transcription Networks
Driving Pallial Regional Development and Evolution
In the cellular blastoderm of Drosophila, enhancer activities
reveal developmental domains generated by the combinatorial
activity of TFs that ultimately underlie body subdivisions, as
exemplified by enhancers that drive gap-gene expression (Perry
et al., 2011). Enhancer activity domains can be smaller and
sharper than the expression domains of the TFs that drive their
expression (Perry et al., 2011).
In thepallial primordiumCoupTFI,Dmrta2 (Dmrt5),Emx2,Lhx2,
Pax6, Pbx1, and Sp8, TFs that control pallial regionalization, are
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Enhancers Active in Cortical Protodomainsexpressed in broad gradients (Bishop et al., 2000; Galceran et al.,
2000; Yunet al., 2001;Mallamaci andStoykova,2006;Armentano
et al., 2007; Sahara et al., 2007; Faedo et al., 2008;Mangale et al.,
2008; Chou et al., 2009; Konno et al., 2012; Borello et al., 2013;
Saulnier et al., 2013). Positional information appears to lie in these
TF gradients, and in their combinatorial interactions.
Here, we provide evidence for a mechanism that can integrate
this transcriptional information to generate discrete pallial
subdivisions. Many of the enhancers show patterns of activity
at E11.5 that are more discrete than the broadly expressed pat-
terns of aforementioned patterning TFs. Thus, we suggest these
enhancer activities reflect the integration of transcriptional
activities that together pattern the pallium. Furthermore, it is
possible that these and related enhancers are fundamental
elements that have driven pallial evolution, as duplication and
transposition of these distant-acting regulators have the poten-
tial to alter gene expression. Significantly, our gain-of-function
transgenic assays show the ability of these enhancers to function
in a variety of chromosomal locations.
Currently, we do not have definitive evidence for the gene(s)
that each of these enhancers regulates. However, based on
proximity, and similar expression profiles, we have some predic-
tions for enhancer/gene pairs (Figure S2 and Table S2). For
instance, the activity of enhancers 1,006, 1,050, and 1,172,
which have genomic positions close to Wnt8b, Lef1, and
CoupTFI, respectively, closely resembles the pallial expression
of these genes (Figures S2J, S2K, and S2M; Visel et al., 2013).
Future studies are required to test for enhancer/gene interac-
tions using chromatin conformation methods (Clowney et al.,
2012), as well as loss-of-function mutagenesis. While some en-
hancers are clearly required for gene expression (Shim et al.,
2012), there is evidence that enhancer redundancy exists (Ahituv
et al., 2007; Lagha et al., 2012).
Mechanisms that Regulate Enhancer Activity
We used informatic, biochemical, and genetic approaches to
begin deciphering transcriptional mechanisms that control the
activity of the enhancers. Informatic methods provide insights
into candidate TFs that may regulate enhancer activities (Shim
et al., 2012; Visel et al., 2013). We used a machine learning
method to identify nucleotide signatures that may underlie
regional differences in enhancer activities. Transcriptional bind-
ing sites that were enriched in enhancers with and without MP
activity led us to identify TFs with expression either in, or
excluded from, the Ch/F part of the E11.5 MP (Figures S3 and
S4). This is interesting because histogenesis of the primordium
of the choroid plexus (Ch) is distinct from the rest of the pallium,
as the Ch is a nonneural tissue generated from the neural tube
roof plate (Puelles, 2014), and the fimbrial area (cortical hem) rep-
resents the border between roof and alar plate tissues. As more
pallial enhancers are defined, and as the binding sites for addi-
tional TFs are identified, it is likely that informatic approaches
will gain power in defining sequences that control regional
expression.
Next, we used ChIP-seq to test whether the enhancers under
study were bound in vivo in the E12.5 mouse cortex by PAX6,
COUPTFI, and PBX1, three transcription factors that regulate
pallial patterning (Bishop et al., 2000; Yun et al., 2001; Mallamaciand Stoykova, 2006; Armentano et al., 2007; Sahara et al., 2007;
Faedo et al., 2008; Borello et al., 2013; O.G. and J.L.R.R., unpub-
lished data). Previous analyses of PAX6 binding in the devel-
oping pallium used ChIP-promoterChIP and thus did not
examine PAX6 binding to the enhancers described herein (San-
som et al., 2009; Xie et al., 2013). Our ChIP-seq analyses showed
that PAX6 (a general marker for the telencephalic pallium;
Puelles et al., 2000) bound to all of the enhancers globally
expressed in the pallium (Figure 7A and Table S8), suggesting
that PAX6 may have a fundamental role coordinating pallial
properties.
Enhancers with more restricted intrapallial regional activity
had reduced frequencies of PAX6 binding, particularly when
LVP activity was absent (Figure 7A and Table S8). In addition,
COUPTFI and PBX1 bound few MP enhancers (Figure 7A and
Table S8). Both Pax6 and CoupTFI regulate dorsoventral
patterning of the pallium; and they both promote ventral identity
(Yun et al., 2001; Faedo et al., 2008). Consequently, our
ChIP-seq analysis provides evidence that these two TFs may
regulate dorsoventral pallial patterning by promoting activity of
enhancers specifically active in the VP, LP, and DP.
This concept is consistent with that the fact that PAX6 has a
potent role in patterning the ventrolateral cortex (Figure 7A;
Yun et al., 2001). Furthermore, transcription assays in tissue
culture showed that PAX6 strongly activated (15-fold) 636,
the enhancer with VP and LP activity (Figure 7B). On the other
hand, PAX6-mediated activation was lower for enhancers with
MP activity (840 and 643), suggesting that they have elements
that antagonize activation by PAX6.
To test hypotheses generated by the ChIP-seq and transfec-
tion assays, we examined 636 and 840 enhancer activities in
Pax6 loss-of-function mutants. As predicted by their PAX6
ChIP-seq peaks and their activation by PAX6 in the cell culture
transcription assay, 636 and 840 pallial activity was greatly
reduced in E11.5 Pax6/ (Figures 7D, 7D0, 7F, and 7F0).
Implications
The identification of human enhancers with restricted spatial and
temporal activities in pallial protodomains demonstrates that the
genome has relatively small (0.5–3 kb) regulatory elements that
can integrate transcriptional information to generate highly
specific patterns of gene expression, even in ectopic genomic
loci (herein and Visel et al., 2013). Importantly, the enhancer
activity patterns for the most part do not resemble the expres-
sion of single known TFs, highlighting the enhancers’ roles as
spatial integrators of regulatory information. This knowledge
opens the door to deciphering the sequence-specific regulation
of enhancer activity and how mutations alter their function and
contribute to disease.
EXPERIMENTAL PROCEDURES
Generation and Characterization of Stable Enhancer Transgenic
Mice
PCR-amplified human enhancer regions were subcloned into Hsp68-
CreERT2-IRES-GFP (Visel et al., 2013) and used to generate stable transgenic
mice. Founders were screened using CreERT2 specific primers. Enhancer
transgenic embryos were examined for GFP expression. For fate mapping,
enhancer lines were crossed to Ai14 Cre-reporter mice (Madisen et al.,Neuron 82, 989–1003, June 4, 2014 ª2014 Elsevier Inc. 1001
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Enhancers Active in Cortical Protodomains2010). Tamoxifen was administered at E9.5 or E10.5; tdtomato was assayed at
later stages. Stable transgenic mice were crossed to the Pax6 mutant.
Mice were used in accordance with National Institutes of Health and UCSF
guidelines.
Histology
Immunohistochemistry was performed as in Flandin et al. (2010). RNA in situ
hybridization and in situ/immunohistochemistry was performed as in Jeong
et al. (2008).
Identification of Region Specific Motifs
See Supplemental Experimental Procedures for details.
Chromatin Immunoprecipitation
ChIP was performed using E12.5 or E13.5 cortex and Pax6 (Millipore),
CoupTf1 (R&D systems), and Pbx1/2/3 (C-20, Santa Cruz Biotechnology)
antibodies (McKenna et al., 2011). Libraries were prepared using an Ovation
Ultralow DR Multiplex System (Nugen). Reads from ChIP, input, and negative
control (IgG) libraries were mapped to the mouse genome (mm9) using BWA
and peaks were called using MACS considering both input and IgG as the
control sample with filtering to remove peaks in repeat regions.
Luciferase Assay
Enhancer activity was studied in P19 cells (Farah et al., 2000) cotransfected
with pCAGGs (empty) or pCAGGs-Pax6/CoupTf1/Pbx1, and Promega
pGL4.23 luciferase reporter (empty) or containing an enhancer element
upstream of the luciferase gene (pGL4.23-enhancer).
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